Are there fewer side effects with ezetimibe than other drugs?

How Ezetimibe's Side Effects Compare to Statins

Ezetimibe, which lowers cholesterol by blocking intestinal absorption, generally causes fewer and milder side effects than statins, the most common cholesterol drugs. Common statin side effects include muscle pain (myalgia in 5-30% of users), liver enzyme elevations, and rare rhabdomyolysis. Ezetimibe's main issues are diarrhea, abdominal pain, and fatigue, affecting 2-4% of patients—far lower incidence.[1][2]

In head-to-head trials like IMPROVE-IT, ezetimibe added to simvastatin increased tolerability, with dropout rates for side effects at 10% versus 13% for statin monotherapy.[3]

Side Effects Versus Other Cholesterol-Lowering Options

• PCSK9 inhibitors (e.g., Repatha, Praluent): These injectables cause injection-site reactions (5-10%) and flu-like symptoms more often than ezetimibe's oral profile, though serious risks are low.[2]
  
• Fibrates (e.g., fenofibrate): Higher rates of gastrointestinal upset, gallstones, and muscle issues (up to 10%) exceed ezetimibe.[1]
  
• Bile acid sequestrants (e.g., cholestyramine): Frequent bloating and constipation (20-30%) make them less tolerable.[2]
  
• Bempedoic acid (Nexletol): Similar low profile to ezetimibe (gout flares, uric acid rises in 1-2%), but ezetimibe edges out on GI complaints.[4]
  
  Ezetimibe monotherapy shows adverse event rates under 5% in most studies, positioning it as a go-to for statin-intolerant patients.[3]
  
  

What Patients Report in Real-World Use

User reviews on platforms like Drugs.com give ezetimibe 5.2/10 for side effects (mild GI focus), better than statins' 4.5/10. Statin users often cite muscle aches as a reason for switching; ezetimibe switchers report 70-80% satisfaction with fewer issues.[5]

When Side Effects Still Matter

Rare allergic reactions or liver issues occur with ezetimibe (<1%), similar to placebo. Combinations like Vytorin (ezetimibe/simvastatin) inherit statin risks. Those with gallbladder disease face slight elevated risk.[1][2]

[1]: FDA Label: Zetia (ezetimibe)
[2]: UpToDate: Ezetimibe overview
[3]: NEJM: IMPROVE-IT Trial (2015)
[4]: FDA Label: Nexletol (bempedoic acid)
[5]: Drugs.com: Ezetimibe Reviews